Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Int Immunopharmacol. 2009 Jan 20;9(3):340–346. doi: 10.1016/j.intimp.2008.12.012

Fig. 3.

Fig. 3

Br proteolyticly cleaves CD25 from activated CD4+ T cells. CD4+CD25− T cells (1×106) were stimulated in vitro with anti-CD3 (10 µg/ml) for 48 h. Activated T cells (1×106) cells were removed from stimulation, washed thrice, and re-plated with or without Br (25 and 50 µg/ml) for 8 h. Post Treatment cell culture supernatant (CS) was evaluated for the presence of CD25 protein via A)Western Blot and B) ELISA. A) Lane 2 = CS from control-media treated cells; lanes 3 and 4 = CS from Br 25 µg/ml; lanes 5 and 6 = CS from Br 50 µg/ml; and lane 7 = CS from E64 Inactivated Br cell cultures. B) The presence of CD25 (IL-2Rα) was detected at low levels in control-media treated cells and was significantly elevated in the CS of Br (50 µg/ml) treated cells. E64 Inactivated Br cell cultures had decreased detectable levels of CD25. Data presented are means of duplicate experiments. * represents p≤0.01 as compared to control, and ** represents p≤0.01 as compared to Br 50.